However, according to the 2020 International Cancer of the Pancreas Screening Consortium (CAPS), PDAC surveillance is recommended in CDKN2A carriers regardless of family history of PDAC, starting at age 40 or 10 years before than the youngest relative affected [19]. This evidence concerns the gene CDKN2A and cancer.